Ventyx Biosciences, Inc.
VTYX
$1.20
-$0.06-4.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -135.12M | -152.52M | -171.30M | -192.60M | -192.96M |
| Total Depreciation and Amortization | 1.35M | 1.44M | 1.39M | 1.22M | 941.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.46M | 14.33M | 17.36M | 19.71M | 19.69M |
| Change in Net Operating Assets | -10.56M | -22.52M | -5.93M | -11.55M | 5.81M |
| Cash from Operations | -130.87M | -159.28M | -158.48M | -183.23M | -166.52M |
| Capital Expenditure | -241.00K | -446.00K | -494.00K | -629.00K | -514.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -15.27M | 42.06M | 51.76M | 162.23M | 101.45M |
| Cash from Investing | -15.51M | 41.62M | 51.26M | 161.60M | 100.94M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 96.42M | 96.63M | 98.32M | 100.84M | 53.33M |
| Repurchase of Common Stock | -906.00K | -906.00K | -906.00K | -- | -- |
| Issuance of Preferred Stock | 26.85M | 26.85M | -- | -- | -- |
| Repurchase of Preferred Stock | -247.00K | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 151.00K | 73.00K | 25.00K | 0.00 |
| Cash from Financing | 122.12M | 122.73M | 97.49M | 100.87M | 53.33M |
| Foreign Exchange rate Adjustments | -55.00K | 92.00K | -84.00K | -37.00K | -12.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -24.32M | 5.16M | -9.82M | 79.20M | -12.27M |